Antibody persistence after primary immunization with trivalent oral poliovirus vaccine
- PMID: 195265
Antibody persistence after primary immunization with trivalent oral poliovirus vaccine
Abstract
Five years after primary infant immunization with trivalent oral poliovirus vaccine, employing either a three-dose primary series as recommended by the U.S. Public Health Service Advisory Committee on Immunization Practices (ACIP) or a four-dose series as recommended by the Committee on Infectious Diseases of the American Academy of Pediatrics. 115 children were serologically tested for persistence of neutralizing antibodies by the microneutralization test. Of the 57 individuals immunized according to the ACIP recommendation, antibody persistence was demonstrated in 92% for type 1 poliovirus, 98% for type 2, and 84% for type 3. Of those 58 individuals originally receiving a four-dose primary infant immunization series, the persistence of antibody was 98% to type 1, 98% to type 2, and 87% to type 3. Twenty-one of 24 negative sera showed neutralizing ability when tested by a more sensitive plaque reduction test. Thus, individuals completing either immunization schedule demonstrated satisfactory persistence of neutralizing antibody to all three poliovirus types over a five-year period.
Similar articles
-
Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.Bull World Health Organ. 1994;72(2):221-5. Bull World Health Organ. 1994. PMID: 8205641 Free PMC article.
-
Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.Bull World Health Organ. 1999;77(6):484-91. Bull World Health Organ. 1999. PMID: 10427933 Free PMC article. Clinical Trial.
-
Early immunization of neonates with trivalent oral poliovirus vaccine.Bull World Health Organ. 1992;70(1):85-91. Bull World Health Organ. 1992. PMID: 1314711 Free PMC article. Clinical Trial.
-
Poliovirus neutralizing antibody persistence after vaccination with the Sabin vaccine: a follow-up study.Ann Clin Lab Sci. 1995 Mar-Apr;25(2):200-6. Ann Clin Lab Sci. 1995. PMID: 7785968
-
Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).Arch Pediatr Adolesc Med. 2004 Dec;158(12):1106-12. doi: 10.1001/archpedi.158.12.1106. Arch Pediatr Adolesc Med. 2004. PMID: 15583093 Review.
Cited by
-
The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.Bull World Health Organ. 1985;63(6):1151-69. Bull World Health Organ. 1985. PMID: 3914926 Free PMC article. Review.
-
Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.Bull World Health Organ. 1994;72(6):973-83. Bull World Health Organ. 1994. PMID: 7867144 Free PMC article. Review.
-
Paralytic poliomyelitis in Italy (1981-85).Eur J Epidemiol. 1987 Mar;3(1):54-60. doi: 10.1007/BF00145073. Eur J Epidemiol. 1987. PMID: 3582600
-
The periodic health examination. Canadian Task Force on the Periodic Health Examination.Can Med Assoc J. 1979 Nov 3;121(9):1193-254. Can Med Assoc J. 1979. PMID: 115569 Free PMC article. No abstract available.
-
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2. Cochrane Database Syst Rev. 2019. PMID: 31801180 Free PMC article.